How do you convert hydromorphone from oral to IV?
A common clinical conversion uses an approximate 5:1 potency ratio when switching from oral hydromorphone to intravenous (IV) hydromorphone: IV dosing is about one-fifth of the total oral daily dose. For an opioid-naïve or careful conversion, dosing is often reduced further to account for incomplete cross-tolerance.
Because exact conversions depend on formulation, prior tolerance, and patient factors, many facilities use an institutional conversion table rather than a single universal number.
What conversion ratio is typically used (5:1 or something else)?
The practical rule of thumb most clinicians use is:
- Oral hydromorphone → IV hydromorphone: divide the oral dose by 5
Example (using the rule of thumb):
- If a patient takes 10 mg oral hydromorphone over 24 hours, the estimated IV hydromorphone requirement would be about 2 mg over 24 hours.
If you tell me the oral mg per dose and how often (or the total daily mg), I can calculate the corresponding IV total and an interval schedule.
How should the converted IV dose be scheduled (bolus vs continuous)?
Oral-to-IV conversion gives an IV total daily amount, but how it’s delivered can vary:
- Divided into scheduled IV doses (e.g., every 4 hours), or
- Given as a continuous infusion with breakthrough doses
Breakthrough IV doses are usually a fraction of the total daily IV dose, sized to provide rapid symptom relief while avoiding oversedation.
If you share whether this is for scheduled dosing or breakthrough dosing, I can suggest a matching interval framework.
What risks can change the “correct” conversion (tolerance, frailty, renal impairment)?
Hydromorphone IV dosing can be riskier in patients with:
- Opioid-naïve status or recent opioid changes (higher risk of oversedation)
- Frailty/low body weight
- Renal impairment (metabolites can accumulate with some opioids, increasing adverse effects)
- Concomitant CNS depressants (benzodiazepines, alcohol, sedating antihistamines)
In practice, clinicians often apply a conservative reduction from the simple ratio for safer initiation or re-titration.
Is the conversion the same for immediate-release vs extended-release?
The potency ratio is generally based on total opioid exposure, but extended-release (ER) products complicate timing:
- ER oral doses need a conversion that matches the 24-hour opioid exposure.
- Dosing frequency for IV may differ from the ER schedule.
If you provide the product (e.g., IR vs ER) and the schedule, the safest way to distribute the IV dose can be determined.
Can you give a quick worked example?
If a patient is taking oral hydromorphone 4 mg by mouth every 4 hours (total 24 mg/day):
- Estimated IV total daily dose = 24 ÷ 5 = 4.8 mg/day IV
Then the IV dose could be divided across the chosen interval (for example, every 4 hours would be 1.2 mg per dose), with typical clinical adjustments for patient safety and breakthrough dosing.
What I need from you to calculate the exact IV dose
Reply with:
1) Oral hydromorphone dose (mg)
2) How often (every how many hours)
3) Total daily oral dose (if you know it)
4) IR or ER formulation
5) Patient context: opioid-naïve vs tolerant, and whether renal impairment/sedatives are involved
Then I’ll compute the IV total daily amount and a common dosing schedule based on your interval preference.